Danhui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danhui Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jinghua Chen
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, 214122, China
1 shared publication - Jun Sun
Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China
1 shared publication - Liping Teng
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
1 shared publication - Min Zhu
Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China
1 shared publication - Teng Wang
Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
1 shared publication - Zhou Zhou
Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China
1 shared publication
Latest Publications
- Open Access
- 12 April 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (4) , 2681-2694
A Preliminary Study on the Relationship between Serum Heparan Sulfate and Cancer-Related Cognitive Impairment: The Moderating Role of Oxidative Stress in Patients with Colorectal Cancer
Cancer-related cognitive impairment (CRCI) has been frequently reported in colorectal cancer survivors. Heparan sulfate (HS) was gradually considered to be related to cognitive disorders. The effect and potential mechanism of HS on CRCI in colorectal cancer patients were unexplored. In this study, all participants were divided into a cognitive impaired group and a cognitive normal group. The concentrations of oxidative stress factors and HS in serum were detected. Associations among HS, oxidative stress factors and CRCI were evaluated. Participants with cognitive impairment exhibited increased levels of HS, GSH, SOD and MDA, compared to the patients with normal cognitive performance. The independent significant association was found between HS and CRCI after controlling for various covariates. The higher concentrations of HS were related to the decreased cognitive performance among survivors who reported higher levels of GSH (β = 0.080, p = 0.002). Moreover, the nonlinear association between the level of HS and cognitive scores was confirmed using the restricted cubic splines (p < 0.001). These results indicated that the increased concentrations of circulating HS had a nonlinear negative connection with cognitive performance in colorectal cancer survivors, which was moderated by GSH. HS might be a new biomolecule for the identification and management of patients with CRCI.
- 12 April 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (4) , 2681-2694
Open AccessA Preliminary Study on the Relationship between Serum Heparan Sulfate and Cancer-Related Cognitive Impairment: The Moderating Role of Oxidative Stress in Patients with Colorectal Cancer
Cancer-related cognitive impairment (CRCI) has been frequently reported in colorectal cancer survivors. Heparan sulfate (HS) was gradually considered to be related to cognitive disorders. The effect and potential mechanism of HS on CRCI in colorectal cancer patients were unexplored. In this study, all participants were divided into a cognitive impaired group and a cognitive normal group. The concentrations of oxidative stress factors and HS in serum were detected. Associations among HS, oxidative stress factors and CRCI were evaluated. Participants with cognitive impairment exhibited increased levels of HS, GSH, SOD and MDA, compared to the patients with normal cognitive performance. The independent significant association was found between HS and CRCI after controlling for various covariates. The higher concentrations of HS were related to the decreased cognitive performance among survivors who reported higher levels of GSH (β = 0.080, p = 0.002). Moreover, the nonlinear association between the level of HS and cognitive scores was confirmed using the restricted cubic splines (p < 0.001). These results indicated that the increased concentrations of circulating HS had a nonlinear negative connection with cognitive performance in colorectal cancer survivors, which was moderated by GSH. HS might be a new biomolecule for the identification and management of patients with CRCI.